Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer
November 27th 2017Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.
Watch
How the Treatment Paradigm for EGFR+ Lung Cancer Will Transform
November 27th 2017Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.
Watch
The Influence of the Gut Microbiome on Response to Anti-PD-1 Therapy in Melanoma
November 16th 2017Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.
Watch
Identifying Unique Antigen Qualities in Long-Term Pancreatic Cancer Survivors
November 16th 2017Vinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Watch
FDA-Approved Agents for the Treatment of MCL
November 15th 2017Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the agents approved by the FDA for the treatment of mantle cell lymphoma (MCL), including acalabrutinib (Calquence) and bortezomib (Velcade).
Watch
An Overview of an Immuno-Oncology Panel for Standardized Profiling of Immune Status
November 15th 2017Ralf Huss, MD, Chief Medical Officer of Definiens, discusses a new immuno-oncology panel introduced by Definiens during the The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. The goal of the panel is to standardize the immunoprofiling of tumors to better predict response to immuno-oncology treatment.
Watch
Comparing Alectinib Versus Crizotinib in ALK+ NSCLC
November 13th 2017David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+ non–small cell lung cancer (NSCLC).
Watch
Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers
November 12th 2017Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Watch
Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 Blockade
November 11th 2017Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Watch
Treating Patients With Stage IV Lung Adenocarcinoma Without Actionable Oncogenic Drivers
November 11th 2017H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses appropriate treatment for patients with stage IV adenocarcinoma who do not harbor oncogenic drivers.
Watch
Evolving Paradigm of Gastrointestinal Cancers
November 10th 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the evolving paradigm of gastrointestinal cancers.
Watch
Improved Understanding of JAK2 Inhibition in Polycythemia Vera
November 9th 2017John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.
Watch
Dr. Luke Discusses the Combination of PD-1 and IDO Inhibitors in Melanoma
November 7th 2017Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br />
Watch
Dr. Chan Discusses Cabozantinib for the Treatment of NETs
November 1st 2017Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Watch
Expected Findings of the SWOG S1505 Trial in Pancreatic Cancer
October 27th 2017Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Watch
Identifying Characteristics of Ovarian Cancer, Other Tumor Subtypes
October 26th 2017Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study that explored the different characteristics of subtypes of ovarian cancer, peritoneal tumors, and fallopian tube tumors.
Watch